Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 145 No. 3132 (2015)

Adenocarcinoma of the gastrointestinal tract in lung transplanted patients with cystic fibrosis: case series and review of the literature

  • Christian Murer
  • Urs Bürgi
  • Malcolm Kohler
  • Christian Benden
  • Lars C. Huber
DOI
https://doi.org/10.4414/smw.2015.14165
Cite this as:
Swiss Med Wkly. 2015;145:w14165
Published
26.07.2015

Abstract

Cystic fibrosis (CF) is one of the most common genetic disorders. Mutations of the cystic fibrosis transmembrane regulator causes dysfunction of epithelial membranes within the gastrointestinal and respiratory system. Patients with CF are known to be at risk for gastrointestinal malignancies, and lung transplantation further increases this risk. We report a case series of three CF patients who developed adenocarcinoma of the gastrointestinal tract in the posttransplant setting. One of these case histories describes a gastric cancer, which is a novel and to date unreported observation. These data emphasise the importance of checking CF patients for the development of abdominal complications following lung transplantation.

References

  1. Ratjen F, Döring G. Cystic fibrosis. The Lancet. 2003;361(9358):681–9.
  2. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29(3):522–6.
  3. O’Sullivan BP, Freedman SD. Cystic fibrosis. The Lancet. Elsevier Ltd; 2009;373(9678):1891–904.
  4. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation_ Thirtieth Adult Lung and Heart-Lung Transplant Report – 2013; Focus Theme_ Age. HEALUN. Elsevier; 2013;32(10):965–78.
  5. A B. Update on cystic fibrosis: selected aspects related to lung transplantation. 2003:1–8.
  6. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001;286(21):2683–9.
  7. Aurora P, Whitehead B, Wade A, Bowyer J, Whitmore P, Rees PG, et al. Lung transplantation and life extension in children with cystic fibrosis. The Lancet. 1999;354(9190):1591–3.
  8. Hofer M, Benden C, Inci I, Schmid C, Irani S, Speich R, et al. True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience. J Heart Lung Transplant. 2009;28(4):334–9.
  9. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United States. JNCI Journal of the National Cancer Institute. 2013;105(2):122–9.
  10. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. JNCI Journal of the National Cancer Institute. 2003;95(5):381–7.
  11. Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332(8):494–9.
  12. Petrowsky H, Schuster H, Irani S, Schäfer M, Jochum W, Schmid C, et al. Pancreatic cancer in cystic fibrosis after bilateral lung transplantation. Pancreas. 2006;33(4):430–2.
  13. Inci I, Stanimirov O, Benden C, Kestenholz P, Hofer M, Boehler A, et al. Lung transplantation for cystic fibrosis: a single center experience of 100 consecutive cases. Eur J Cardiothoracic Surg. 2012;41(2):435–40.
  14. Abdul-Karim FW, King TA, Dahms BB, Gauderer MW, Boat TF. Carcinoma of extrahepatic biliary system in an adult with cystic fibrosis. Gastroenterology. 1982;82(4):758–62.
  15. Meyer KC, Francois ML, Thomas HK, Radford KL, Hawes DS, Mack TL, et al. Colon cancer in lung transplant recipients with CF: Increased risk and results of screening. J Cyst Fibros. 2011;10(5):366–9.
  16. Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A. Early Colon Screening of Adult Patients With Cystic Fibrosis Reveals High Incidence of Adenomatous Colon Polyps. J Clin Gastroenterol. 2013:1.
  17. Sampaio MS, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. Transplantation. 2012;94(10):990–8.
  18. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889–96.
  19. Ferlitsch M, Reinhart K, Pramhas S, Wiener C, Gal O, Bannert C, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA. American Medical Association; 2011;306(12):1352–8.
  20. Tizzano EF, Chitayat D, Buchwald M. Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues. Hum Mol Genet. 1993;2(3):219–24.
  21. Tesluk H, McCauley K, Kurland G, Ruebner BH. Cholangiocarcinoma in an adult with cystic fibrosis. J Clin Gastroenterol. 1991;13(4):485–7.
  22. Naderi ASA, Farsian FN, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. Eur J Gastroenterol Hepatol. 2008;20(11):1115–7.
  23. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39.
  24. Wang X-W, Zhang Y-J. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol. 2014;20(15):4178–88.
  25. Kerem E, Conway S, Elborn S, Heijerman H, Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. 2005. pp. 7–26.

Most read articles by the same author(s)

1 2 > >>